首页> 美国卫生研究院文献>BMC Infectious Diseases >Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa
【2h】

Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa

机译:将线探针测定法与BACTEC MGIT 960系统在南非转诊实验室中对一线和二线抗结核药物的药敏试验进行比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe incidence of multidrug-resistant tuberculosis (MDR-TB) is increasing and the emergence of extensively drug-resistant tuberculosis (XDR-TB) is a major challenge. Controlling resistance, reducing transmission and improving treatment outcomes in MDR/XDR-TB patients is reliant on susceptibility testing. Susceptibility testing using phenotypic methods is labour intensive and time-consuming. Alternative methods, such as molecular assays are easier to perform and have a rapid turn-around time. The World Health Organization (WHO) has endorsed the use of line probe assays (LPAs) for first and second line diagnostic screening of MDR/XDR-TB.
机译:背景技术耐多药结核病(MDR-TB)的发病率正在增加,广泛耐药结核病(XDR-TB)的出现是一个重大挑战。在耐多药/广泛耐药结核病患者中,控制抵抗力,减少传播和改善治疗效果取决于药敏试验。使用表型方法进行药敏试验是费力且费时的。替代方法,例如分子测定法,更易于执行且周转时间短。世界卫生组织(WHO)已批准将线探针测定法(LPA)用于MDR / XDR-TB的一线和二线诊断筛查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号